G4.2 Kilder

Legemiddeldosering ved mage- og tarmsykdom, leversykdom, hjertesykdom og nevrologisk sykdom

Helsebiblioteket, emnebibliotek legemidler, preparatomtaler (SPC) www.helsebiblioteket.no/legemidler

European Medicines Agency (EMA), EPARs for authorised medicinal products for human use www.ema.europa.eu/htms/human/epar/a.htm

British National Formulary (BNF) 62 September 2011. ISBN 978-0-85369-981-1 www.bnf.org

McMurray JJV, Adamopoulos S, Anker SD, et al.: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Heart Journal, doi:10.1093/eurheartj/ehs104, 2012; Eur Heart J. 2012 May 19. (e-pub ahead of print)

Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ,Bart BA, Mascette AM, Braunwald E, O’Connor CM. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364: 797–805

Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100:2312–2318

Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21

McMurray J, Cohen-Solal A, Dietz R, Eichhorn E, Erhardt L, Hobbs FD, Krum H, Maggioni A, McKelvie RS, Pina IL, Soler-Soler J, Swedberg K. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur J Heart Fail 2005;7:710–721

Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA. Effects of highdose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009;374:1840–1848

Hood WB Jr, Dans AL, Guyatt GH, Jaeschke R, McMurray JJ. Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. J Card Fail 2004;10:155–164

Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, Austin PC, Laupacis A, Stukel TA. Cyclo-oxygenase-2 inhibitors versus non-selective nonsteroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004;363:1751–1756

Pollack, CV, Reilly, PA, Eikelboom J et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 372: Epub ahead of print

Nevro-NEL. Norsk nevrologisk forenings prosedyrer 2015.

Elsais A, Popperud TH, Melien Ø, Kerty E. Medikamenter som kan utløse og forverre myasthenia gravis. Tidsskr Nor Legeforen 2013; 133: 296-9.

Henning OJ, Nakken KO. Psychiatric comorbidity and use of psychotropic drugs in epilepsy patients. Acta Neurol Scand Suppl 2010; 190: 18-22

Perez-Lloret S, Rascol O. Parkinson disease: serotonin reuptake inhibitors for depression in PD. Nature reviews Neurol 2012; 5 juni (e-pub ahead of print)

Friedman JH. Atypical antipsychotic drugs in the treartment of parkinsons disease. J Pharm Pract 2011; 24: 534-40